蛋白酶抑制剂(药理学)
2019年冠状病毒病(COVID-19)
大流行
蛋白酶
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019-20冠状病毒爆发
化学
冠状病毒
病毒学
临床试验
药理学
药物发现
冠状病毒感染
药品
计算生物学
病毒
病毒载量
疾病
内科学
传染病(医学专业)
酶
生物信息学
医学
生物
生物化学
抗逆转录病毒疗法
爆发
标识
DOI:10.1021/acs.jmedchem.2c00624
摘要
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.
科研通智能强力驱动
Strongly Powered by AbleSci AI